Abstract
Substance use disorders are a leading cause of morbidity and mortality, and available pharmacological treatments are of modest efficacy. Histamine is a biogenic amine with four types of receptors. The histamine H3 receptor (H3R) is an autoreceptor and also an heteroreceptor. H3Rs are highly expressed in the basal ganglia, hippocampus and cortex, and regulate a number of neurotransmitters including acetylcholine, norepinephrine, GABA and dopamine. Its function and localization suggest that the H3R may be relevant to a number of psychiatric disorders and could represent a potential therapeutic target for substance use disorders. The purpose of the present review is to summarize preclinical studies investigating the effects of H3R agonists and antagonists on animal models of alcohol, nicotine and psychostimulant use. At present, the effects of H3R antagonists such as thioperamide, pitolisant or ciproxifan have been investigated in drug-induced locomotion, conditioned place preference, drug self-administration, reinstatement, sensitization and drug discrimination. For alcohol and nicotine, the effects of H3R ligands on two-bottle choice and memory tasks, respectively, have also been investigated. The results of these studies are inconsistent. For alcohol, H3R antagonists generally decreased the reward-related properties of ethanol, which suggests that H3R antagonists may be effective as a treatment option for alcohol use disorder. However, the effects of H3R antagonists on nicotine and psychostimulant motivation and reward are less clear. H3R antagonists potentiated the abuse-related properties of nicotine, but only a handful of studies have been conducted. For psychostimulants, evidence is mixed and suggests that more research is needed to establish whether H3R antagonists are a viable therapeutic option. The fact that different drugs of abuse have different brain targets may explain the differential effects of H3R ligands.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alleva L, Tirelli E, Brabant C (2013) Therapeutic potential of histaminergic compounds in the treatment of addiction and drug-related cognitive disorders. Behav Brain Res 237:357–368. https://doi.org/10.1016/j.bbr.2012.09.025
Arias-Montano JA, Floran B, Garcia M, Aceves J, Young JM (2001) Histamine H(3) receptor-mediated inhibition of depolarization-induced, dopamine D(1) receptor-dependent release of [(3)H]-gamma-aminobutyric acid from rat striatal slices. Br J Pharmacol 133(1):165–171. https://doi.org/10.1038/sj.bjp.0704053
Arrang JM, Garbarg M, Schwartz JC (1983) Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 302(5911):832–837. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/6188956
Bahi A, Sadek B, Schwed SJ, Walter M, Stark H (2013) Influence of the novel histamine H(3) receptor antagonist ST1283 on voluntary alcohol consumption and ethanol-induced place preference in mice. Psychopharmacology (Berl) 228(1):85–95. https://doi.org/10.1007/s00213-013-3019-7
Bahi A, Sadek B, Nurulain SM, Lazewska D, Kiec-Kononowicz K (2015) The novel non-imidazole histamine H3 receptor antagonist DL77 reduces voluntary alcohol intake and ethanol-induced conditioned place preference in mice. Physiol Behav 151:189–197. https://doi.org/10.1016/j.physbeh.2015.07.012
Banks ML, Manvich DF, Bauzo RM, Howell LL (2009) Effects of histamine H(3) receptor activation on the behavioral-stimulant effects of methamphetamine and cocaine in mice and squirrel monkeys. Pharmacology 83(3):164–169. https://doi.org/10.1159/000191473
Barbier AJ, Berridge C, Dugovic C, Laposky AD, Wilson SJ, Boggs J et al (2004) Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist. Br J Pharmacol 143(5):649–661. https://doi.org/10.1038/sj.bjp.0705964
Blandina P, Giorgetti M, Cecchi M, Leurs R, Timmerman H, Giovannini MG (1996) Histamine H3 receptor inhibition of K(+)-evoked release of acetylcholine from rat cortex in vivo. Inflamm Res 45(Suppl 1):S54–S55. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/8696930
Bonaventure P, Letavic M, Dugovic C, Wilson S, Aluisio L, Pudiak C et al (2007) Histamine H3 receptor antagonists: from target identification to drug leads. Biochem Pharmacol 73(8):1084–1096. https://doi.org/10.1016/j.bcp.2006.10.031
Brabant C, Charlier Y, Quertemont E, Tirelli E (2005) The H3 antagonist thioperamide reveals conditioned preference for a context associated with an inactive small dose of cocaine in C57BL/6J mice. Behav Brain Res 160(1):161–168. https://doi.org/10.1016/j.bbr.2004.11.029
Brabant C, Quertemont E, Tirelli E (2006) Effects of the H3-receptor inverse agonist thioperamide on the psychomotor effects induced by acutely and repeatedly given cocaine in C57BL/6J mice. Pharmacol Biochem Behav 83(4):561–569. https://doi.org/10.1016/j.pbb.2006.03.018
Brabant C, Alleva L, Grisar T, Quertemont E, Lakaye B, Ohtsu H et al (2009) Effects of the H3 receptor inverse agonist thioperamide on cocaine-induced locomotion in mice: role of the histaminergic system and potential pharmacokinetic interactions. Psychopharmacology (Berl) 202(4):673–687. https://doi.org/10.1007/s00213-008-1345-y
Brabant C, Charlier Y, Tirelli E (2013) The histamine H(3)-receptor inverse agonist pitolisant improves fear memory in mice. Behav Brain Res 243:199–204. https://doi.org/10.1016/j.bbr.2012.12.063
Brabant C, Charlier Y, Navacerrada MES, Alleva L, Tirelli E (2016) Action of pitolisant on the stimulant and rewarding effects of cocaine in mice. Eur J Pharmacol 791:552–559. https://doi.org/10.1016/j.ejphar.2016.08.027
Calik MW (2017) Update on the treatment of narcolepsy: clinical efficacy of pitolisant. Nat Sci Sleep 9:127–133. https://doi.org/10.2147/NSS.S103462
Campbell VC, Kopajtic TA, Newman AH, Katz JL (2005) Assessment of the influence of histaminergic actions on cocaine-like effects of 3alpha-diphenylmethoxytropane analogs. J Pharmacol Exp Ther 315(2):631–640. https://doi.org/10.1124/jpet.105.090829
Clapham J, Kilpatrick GJ (1994) Thioperamide, the selective histamine H3 receptor antagonist, attenuates stimulant-induced locomotor activity in the mouse. Eur J Pharmacol 259(2):107–114. https://doi.org/10.1016/0014-2999(94)90498-7
Cowart M, Gfesser GA, Browman KE, Faghih R, Miller TR, Milicic I et al (2007) Novel heterocyclic-substituted benzofuran histamine H3 receptor antagonists: in vitro properties, drug-likeness, and behavioral activity. Biochem Pharmacol 73(8):1243–1255. https://doi.org/10.1016/j.bcp.2007.02.010
de Biase S, Pellitteri G, Gigli GL, Valente M (2021) Evaluating pitolisant as a narcolepsy treatment option. Expert Opin Pharmacother 22(2):155–162. https://doi.org/10.1080/14656566.2020.1817387
de Wit H, Stewart J (1981) Reinstatement of cocaine-reinforced responding in the rat. Psychopharmacology (Berl) 75(2):134–143. Retrieved from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=6798603
Di Chiara G, Acquas E, Carboni E (1991) The mesolimbic dopamine system: from motivation to action. Role of mesolimbic dopamine in the motivational effects of drugs: Brain dialysis and place preference studies. In: Willner P, Scheel-Kruger J (eds) . Wiley, pp 367–384
Epstein DH, Preston KL (2003) The reinstatement model and relapse prevention: a clinical perspective. Psychopharmacology (Berl) 168(1–2):31–41. Retrieved from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12721778
Eriksson K (1968) Genetic selection for voluntary alcohol consumption in the albino rat. Science 159(3816):739–741. https://doi.org/10.1126/science.159.3816.739
Ferrada C, Ferre S, Casado V, Cortes A, Justinova Z, Barnes C, Canela EI, Goldberg SR, Leurs R, Lluis C, Franco R (2008) Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function. Neuropharmacology 55(2):190–197. https://doi.org/10.1016/j.neuropharm.2008.05.008
Fox GB, Esbenshade TA, Pan JB, Radek RJ, Krueger KM, Yao BB, Browman KE, Buckley MJ, Ballard ME, Komater VA, Miner H, Zhang M, Faghih R, Rueter LE, Bitner RS, Drescher KU, Wetter J, Marsh K, Lemaire M, Porsolt RD, Bennani YL, Sullivan JP, Cowart MD, Decker MW, Hancock AA (2005) Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. J Pharmacol Exp Ther 313(1):176–190. https://doi.org/10.1124/jpet.104.078402
Galici R, Boggs JD, Aluisio L, Fraser IC, Bonaventure P, Lord B, Lovenberg TW (2009) JNJ-10181457, a selective non-imidazole histamine H(3) receptor antagonist, normalizes acetylcholine neurotransmission and has efficacy in translational rat models of cognition. Neuropharmacology 56(8):1131–1137. https://doi.org/10.1016/j.neuropharm.2009.03.011
Galici R, Rezvani AH, Aluisio L, Lord B, Levin ED, Fraser I, Boggs J, Welty N, Shoblock JR, Motley ST, Letavic MA, Carruthers NI, Dugovic C, Lovenberg TW, Bonaventure P (2011) JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats. Psychopharmacology (Berl) 214(4):829–841. https://doi.org/10.1007/s00213-010-2092-4
Garcia-Ramirez M, Aceves J, Arias-Montano JA (2004) Intranigral injection of the H3 agonist immepip and systemic apomorphine elicit ipsilateral turning behaviour in naive rats, but reduce contralateral turning in hemiparkinsonian rats. Behav Brain Res 154(2):409–415. https://doi.org/10.1016/j.bbr.2004.03.007
Griebel G, Decobert M, Jacquet A, Beeske S (2012) Awakening properties of newly discovered highly selective H(3) receptor antagonists in rats. Behav Brain Res 232(2):416–420. https://doi.org/10.1016/j.bbr.2012.04.033
Hancock AA, Bennani YL, Bush EN, Esbenshade TA, Faghih R, Fox GB, Jacobson P, Knourek-Segel V, Krueger KM, Nuss ME, Pan JB, Shapiro R, Witte DG, Yao BB (2004) Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist. Eur J Pharmacol 487(1–3):183–197. https://doi.org/10.1016/j.ejphar.2004.01.015
Harwell V, Fasinu PS (2020) Pitolisant and other histamine-3 receptor antagonists-an update on therapeutic potentials and clinical prospects. Medicines (Basel) 7(9). https://doi.org/10.3390/medicines7090055
Hu W, Chen Z (2017) The roles of histamine and its receptor ligands in central nervous system disorders: An update. Pharmacol Ther 175:116–132. https://doi.org/10.1016/j.pharmthera.2017.02.039
Huyts B, Brabant C, Tirelli E (2019) Pitolisant and intravenous cocaine self-administration in mice. Eur J Pharmacol 851:63–68. https://doi.org/10.1016/j.ejphar.2019.02.019
Jarskog LF, Lowy MT, Grove RA, Keefe RS, Horrigan JP, Ball MP, Breier A, Buchanan RW, Carter CS, Csernansky JG, Goff DC, Green MF, Kantrowitz JT, Keshavan MS, Laurelle M, Lieberman JA, Marder SR, Maruff P, McMahon RP, Seidman LJ, Peykamian MA (2015) A Phase II study of a histamine H(3) receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy. Schizophr Res 164(1–3):136–142. https://doi.org/10.1016/j.schres.2015.01.041
Kholdebarin E, Caldwell DP, Blackwelder WP, Kao M, Christopher NC, Levin ED (2007) Interaction of nicotinic and histamine H(3) systems in the radial-arm maze repeated acquisition task. Eur J Pharmacol 569(1–2):64–69. https://doi.org/10.1016/j.ejphar.2007.04.051
Kilpatrick GJ, Michel AD (1991) Characterisation of the binding of the histamine H3 receptor agonist [3H] (R)-alpha methyl histamine to homogenates of rat and guinea-pig cortex. Agents Actions Suppl 33:69–75. https://doi.org/10.1007/978-3-0348-7,309-3_4
Kitanaka J, Kitanaka N, Hall FS, Amatsu Y, Hashimoto K, Hisatomi E, Kitao E, Mimura M, Nakamura M, Ozawa R, Sato M, Tagami K, Uhl GR, Takemura M (2020) In vivo evaluation of effects of histamine H3 receptor antagonists on methamphetamine-induced hyperlocomotion in mice. Brain Res 1740:146873. https://doi.org/10.1016/j.brainres.2020.146873
Komater VA, Browman KE, Curzon P, Hancock AA, Decker MW, Fox GB (2003) H3 receptor blockade by thioperamide enhances cognition in rats without inducing locomotor sensitization. Psychopharmacology (Berl) 167(4):363–372. https://doi.org/10.1007/s00213-003-1431-0
Kruk M, Miszkiel J, McCreary AC, Przegalinski E, Filip M, Biala G (2012) Effects of the histamine H(3) receptor antagonist ABT-239 on cognition and nicotine-induced memory enhancement in mice. Pharmacol Rep 64(6):1316–1325. https://doi.org/10.1016/s1734-1140(12)70929-5
Kubo M, Kishi T, Matsunaga S, Iwata N (2015) Histamine H3 receptor antagonists for Alzheimer’s disease: a systematic review and meta-analysis of randomized placebo-controlled trials. J Alzheimers Dis 48(3):667–671. https://doi.org/10.3233/JAD-150393
Lamb YN (2020) Pitolisant: a review in narcolepsy with or without cataplexy. CNS Drugs 34(2):207–218. https://doi.org/10.1007/s40263-020-00703-x
Lazewska D, Kiec-Kononowicz K (2010) Recent advances in histamine H3 receptor antagonists/inverse agonists. Expert Opin Ther Pat 20(9):1147–1169. https://doi.org/10.1517/13543776.2010.509346
Leshner AI (1997) Addiction is a brain disease, and it matters. Science 278:45–47
Letavic MA, Aluisio L, Atack JR, Bonaventure P, Carruthers NI, Dugovic C, Everson A, Feinstein MA, Fraser IC, Hoey K, Jiang X, Keith JM, Koudriakova T, Leung P, Lord B, Lovenberg TW, Ly KS, Morton KL, Timothy Motley S, Nepomuceno D, Rizzolio M, Rynberg R, Sepassi K, Shelton J (2010) Pre-clinical characterization of aryloxypyridine amides as histamine H3 receptor antagonists: identification of candidates for clinical development. Bioorg Med Chem Lett 20(14):4210–4214. https://doi.org/10.1016/j.bmcl.2010.05.041
Ligneau X, Landais L, Perrin D, Piriou J, Uguen M, Denis E, Robert P, Parmentier R, Anaclet C, Lin J-S, Burban A, Arrang J-M, Schwartz JC (2007a) Brain histamine and schizophrenia: potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649. Biochem Pharmacol 73(8):1215–1224. https://doi.org/10.1016/j.bcp.2007.01.023
Ligneau X, Perrin D, Landais L, Camelin JC, Calmels TP, Berrebi-Bertrand I, Lecomte J-M, Parmentier R, Anaclet C, Lin J-S, Bertaina-Anglade V, la Rochelle CD, d'Aniello F, Rouleau A, Gbahou F, Arrang J-M, Ganellin CR, Stark H, Schunack W, Schwartz JC (2007b) BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: preclinical pharmacology. J Pharmacol Exp Ther 320(1):365–375. https://doi.org/10.1124/jpet.106.111039
Lin JS, Sakai K, Vanni-Mercier G, Arrang JM, Garbarg M, Schwartz JC, Jouvet M (1990) Involvement of histaminergic neurons in arousal mechanisms demonstrated with H3-receptor ligands in the cat. Brain Res 523(2):325–330. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/2169324
Lintunen M, Hyytia P, Sallmen T, Karlstedt K, Tuomisto L, Leurs R, Kiianmaa K, Korpi ER, Panula P (2001) Increased brain histamine in an alcohol-preferring rat line and modulation of ethanol consumption by H(3) receptor mechanisms. FASEB J 15(6):1074–1076. https://doi.org/10.1096/fj.00-0545fje
Martinez-Mir MI, Pollard H, Moreau J, Arrang JM, Ruat M, Traiffort E, Schwartz JC, Palacios JM (1990) Three histamine receptors (H1, H2 and H3) visualized in the brain of human and non-human primates. Brain Res 526(2):322–327. https://doi.org/10.1016/0006-8993(90)91240-h
Medhurst AD, Atkins AR, Beresford IJ, Brackenborough K, Briggs MA, Calver AR, Cilia J, Cluderay JE, Crook B, Davis JB, Davis RK, Davis RP, Dawson LA, Foley AG, Gartlon J, Gonzalez MI, Heslop T, Hirst WD, Jennings C, Jones DNC, Lacroix LP, Martyn A, Ociepka S, Ray A, Regan CM, Roberts JC, Schogger J, Southam E, Stean TO, Trail BK, Upton N, Wadsworth G, Wald JA, White T, Witherington J, Woolley ML, Worby A, Wilson DM (2007) GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer’s disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther 321(3):1032–1045. https://doi.org/10.1124/jpet.107.120311
Miszkiel J, Kruk M, McCreary AC, Przegalinski E, Biala G, Filip M (2011) Effects of the histamine H3 receptor antagonist ABT-239 on acute and repeated nicotine locomotor responses in rats. Pharmacol Rep 63(6):1553–1559. https://doi.org/10.1016/s1734-1,140(11)70720-4
Morais-Silva G, Ferreira-Santos M, Marin MT (2016) Conessine, an H3 receptor antagonist, alters behavioral and neurochemical effects of ethanol in mice. Behav Brain Res 305:100–107. https://doi.org/10.1016/j.bbr.2016.02.025
Motawaj M, Arrang JM (2011) Ciproxifan, a histamine H(3)-receptor antagonist/inverse agonist, modulates methamphetamine-induced sensitization in mice. Eur J Neurosci 33(7):1197–1204. https://doi.org/10.1111/j.1460-9568.2011.07618.x
Munzar P, Nosal R, Goldberg SR (1998) Potentiation of the discriminative-stimulus effects of methamphetamine by the histamine H3 receptor antagonist thioperamide in rats. Eur J Pharmacol 363(2–3):93–101. https://doi.org/10.1016/s0014-2,999(98)00789-4
Munzar P, Tanda G, Justinova Z, Goldberg SR (2004) Histamine h3 receptor antagonists potentiate methamphetamine self-administration and methamphetamine-induced accumbal dopamine release. Neuropsychopharmacology 29(4):705–717. https://doi.org/10.1038/sj.npp.1300380
Nuutinen S, Karlstedt K, Aitta-Aho T, Korpi ER, Panula P (2010) Histamine and H3 receptor-dependent mechanisms regulate ethanol stimulation and conditioned place preference in mice. Psychopharmacology (Berl) 208(1):75–86. https://doi.org/10.1007/s00213-009-1710-5
Nuutinen S, Lintunen M, Vanhanen J, Ojala T, Rozov S, Panula P (2011a) Evidence for the role of histamine H3 receptor in alcohol consumption and alcohol reward in mice. Neuropsychopharmacology 36(10):2030–2040. https://doi.org/10.1038/npp.2011.90
Nuutinen S, Vanhanen J, Pigni MC, Panula P (2011b) Effects of histamine H3 receptor ligands on the rewarding, stimulant and motor-impairing effects of ethanol in DBA/2J mice. Neuropharmacology 60(7–8):1193–1199. https://doi.org/10.1016/j.neuropharm.2010.10.027
Nuutinen S, Vanhanen J, Maki T, Panula P (2012) Histamine h3 receptor: a novel therapeutic target in alcohol dependence? Front Syst Neurosci 6:36. https://doi.org/10.3389/fnsys.2012.00036
Nuutinen S, Maki T, Rozov S, Backstrom P, Hyytia P, Piepponen P, Panula P (2016) Histamine H3 receptor antagonist decreases cue-induced alcohol reinstatement in mice. Neuropharmacology 106:156–163. https://doi.org/10.1016/j.neuropharm.2015.06.006
Panula P (2020) Histamine, histamine H3 receptor, and alcohol use disorder. Br J Pharmacol 177(3):634–641. https://doi.org/10.1111/bph.14634
Panula P, Nuutinen S (2011) Histamine and H3 receptor in alcohol-related behaviors. J Pharmacol Exp Ther 336(1):9–16. https://doi.org/10.1124/jpet.110.170928
Panula P, Chazot PL, Cowart M, Gutzmer R, Leurs R, Liu WL, Stark H, Thurmond RL, Haas HL (2015) International union of basic and clinical pharmacology. XCVIII. Histamine receptors. Pharmacol Rev 67(3):601–655. https://doi.org/10.1124/pr.114.010249
Pascoli V, Boer-Saccomani C, Hermant JF (2009) H3 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing retrieval. Psychopharmacology (Berl) 202(1–3):141–152. https://doi.org/10.1007/s00213-008-1171-2
Passani MB, Benetti F, Blandina P, Furini CRG, de Carvalho Myskiw J, Izquierdo I (2017) Histamine regulates memory consolidation. Neurobiol Learn Mem 145:1–6. https://doi.org/10.1016/j.nlm.2017.08.007
Patel D, Vishwakarma PK, Patel R, Jain NS (2021) Central histaminergic transmission modulates the expression of chronic nicotine withdrawal induced anxiety-like and somatic behavior in mice. Behav Brain Res 399:112997. https://doi.org/10.1016/j.bbr.2020.112997
Richardson NR, Roberts DC (1996) Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. J Neurosci Methods 66(1):1–11. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/8794935
Rusjan P, Sabioni P, Di Ciano P, Mansouri E, Boileau I, Laveille A, Capet M, Duvauchelle T, Schwartz J-C, Robert P, Le Foll B (2020) Exploring occupancy of the histamine H3 receptor by pitolisant in humans using PET. Br J Pharmacol 177(15):3464–3472. https://doi.org/10.1111/bph.15067
Sadek B, Saad A, Sadeq A, Jalal F, Stark H (2016) Histamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases. Behav Brain Res 312:415–430. https://doi.org/10.1016/j.bbr.2016.06.051
Schlicker E, Malinowska B, Kathmann M, Gothert M (1994) Modulation of neurotransmitter release via histamine H3 heteroreceptors. Fundam Clin Pharmacol 8(2):128–137. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/8020871
Schwartz JC (2011) The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br J Pharmacol 163(4):713–721. https://doi.org/10.1111/j.1476-5381.2011.01286.x
Setnik B, McDonnell M, Mills C, Scart-Gres C, Robert P, Dayno JM, Schwartz JC (2020) Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy. Sleep 43(4). https://doi.org/10.1093/sleep/zsz252
Tzschentke TM (1998) Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog Neurobiol 56(6):613–672. Retrieved from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9871940
Uguen M, Perrin D, Belliard S, Ligneau X, Beardsley PM, Lecomte JM, Schwartz JC (2013) Preclinical evaluation of the abuse potential of pitolisant, a histamine H(3) receptor inverse agonist/antagonist compared with Modafinil. Br J Pharmacol 169(3):632–644. https://doi.org/10.1111/bph.12149
Vanhanen J, Nuutinen S, Lintunen M, Maki T, Ramo J, Karlstedt K, Panula P (2013) Histamine is required for H(3) receptor-mediated alcohol reward inhibition, but not for alcohol consumption or stimulation. Br J Pharmacol 170(1):177–187. https://doi.org/10.1111/bph.12170
Wang J, Li X, Yang S, Wang T, Xu Z, Xu J, Gao H, Chen G (2021) Pitolisant versus placebo for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea: a meta-analysis from randomized controlled trials. Pharmacol Res 105:522. https://doi.org/10.1016/j.phrs.2021.105522
Weeks JR, Collins RJ (1964) Factors affecting voluntary morphine intake in self-maintained addicted rats. Psychopharmacologia 6(4):267–279. Retrieved from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=5890552
Wise RA (1978) Catecholamine theories of reward: a critical review. Brain Res 152(2):215–247. Retrieved from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=354753
Wise RA, Bozarth MA (1987) A psychomotor stimulant theory of addiction. Psychol Rev 94(4):469–492. Retrieved from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=3317472
Zhao C, Sun M, Bennani YL, Gopalakrishnan SM, Witte DG, Miller TR, Krueger KM, Browman KE, Thiffault C, Wetter J, Marsh KC, Hancock AA, Esbenshade TA, Cowart MD (2008) The alkaloid conessine and analogues as potent histamine H3 receptor antagonists. J Med Chem 51(17):5423–5430. https://doi.org/10.1021/jm8003625
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Di Ciano, P., Hendershot, C.S., Le Foll, B. (2022). Therapeutic Potential of Histamine H3 Receptors in Substance Use Disorders. In: Yanai, K., Passani, M.B. (eds) The Functional Roles of Histamine Receptors. Current Topics in Behavioral Neurosciences, vol 59. Springer, Cham. https://doi.org/10.1007/7854_2022_372
Download citation
DOI: https://doi.org/10.1007/7854_2022_372
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-16996-0
Online ISBN: 978-3-031-16997-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)